BioClinica®, Inc., (NASDAQ: BIOC), a global provider of
clinical trial management services, announced today that Sanofi
(EURONEXT: SAN and NYSE: SNY), one of the world's largest pharmaceutical
companies, has selected BioClinica's OnPoint as the company's standard
CTMS (Clinical Trial Management System). With this decision, Sanofi
plans to utilize OnPoint CTMS for all clinical trial management activity.
Sanofi is the largest in a growing list of companies that includes other
top ten pharmaceutical and medical device manufacturers to embrace
BioClinica's innovative clinical trial management system, making OnPoint
the leading CTMS solution for forward-thinking companies.
"BioClinica is extremely proud that Sanofi has chosen OnPoint CTMS,"
said Mark Weinstein, CEO of BioClinica. "We look forward to helping
fulfill the long-term vision of Sanofi through the use of embedded and
transformational applications. This is further evidence that our
eClinical solutions are not only leading from a technology perspective,
but that our people, products and services are some of the best in the
industry."
BioClinica's OnPoint CTMS improves clinical trial management by helping
sponsors easily centralize and share trial data. OnPoint's unique
Office-Smart design will maximize Sanofi's existing investment in
Microsoft technologies by letting users access, update, and report on
clinical trial data from within the familiar environment of Microsoft
Office and SharePoint. Using SharePoint as a collaborative portal,
OnPoint's web services integration with other trial management products
provides an end-to-end trial management solution. This approach lessons
the financial impact of trial management, greatly enhances user
adoption, and helps avoid the pitfalls of outdated, legacy CTMS products.
"Providing an end-to-end clinical development platform that unifies the
best available solutions is an important part of BioClinica's approach
to trial management," said Peter Benton, President of BioClinica's
eClinical Solutions. "OnPoint's ability to exchange information across
multiple systems, including Sanofi's choice of eTMF (Electronic Trial
Master File), makes OnPoint the best choice for clinical trial
management and demonstrates why BioClinica is the innovation leader in
eClinical products."
"I am confident that OnPoint is the right CTMS for Sanofi and will help
bring new therapies and treatments to market faster," continued Mr.
Benton. "As part of Sanofi's extensive evaluation process, we conducted
a proof-of-concept implementation which demonstrated how OnPoint met
Sanofi's key business imperatives of collaboration, integration, and
architectural openness."
As a Microsoft Gold partner, BioClinica has long been known for its
industry-leading integration with Microsoft technology. BioClinica was
recently awarded a Microsoft
Life Sciences Innovation Award for creating the OnPoint CTMS
"Monitor Visit Report" which makes it easier for clinical site monitors
to enter essential study information with or without an internet
connection. Andrea McGonigle, national managing director for Life
Sciences at Microsoft Corporation, stated, "BioClinica and Sanofi have
both recognized the power of the Microsoft Platform and are using these
technologies to build the future of how clinical trials will be run. The
power of the Microsoft stack allows scalability and flexibility, and
puts the information back in the users' hands. Instead of monolithic
database architectures, Sanofi will be empowered to 'liberate their
clinical trial data' and make faster decisions."